Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Immunome Inc. (IMNM)

Immunome Q3 2026 net loss widens to $85.8 million; varegacestat PDUFA April 28, 2027

Negative Impact 3 of 5 earnings

Immunome reported a third-quarter 2026 net loss of $85.8 million, or $0.76 per share, up from $57.5 million, or $0.65 per share, a year earlier, with no collaboration revenue in either period. Higher research and development and general and administrative spending drove the wider loss, and the company said its $461.6 million in cash and marketable securities should fund operations into 2028.

Key points

  • Net loss was $85.8 million for the quarter ended September 30, 2026, versus $57.5 million a year earlier; loss per share was $0.76 versus $0.65.
  • Research and development expenses rose to $69.5 million from $49.2 million; general and administrative expenses rose to $20.9 million from $10.9 million.
  • Cash, cash equivalents and marketable securities totaled $461.6 million as of September 30, 2026, which the company expects to fund operations into 2028.
  • The FDA set a PDUFA target action date of April 28, 2027 for varegacestat, and updated IM-1021 Phase 1 data are expected at ASH on December 14, 2026.

The filing

CompanyImmunome Inc. (IMNM)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:05 PM ET
Accession number0001193125-26-453556

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 5:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.